Long-term health-related quality of life of critically ill patients with haematological malignancies: a prospective observational multicenter study.
Anxiety
Depression
Haematological malignancy
Intensive care unit
Long-term health-related quality of life
Post-traumatic syndrome disorder
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
05 Jan 2019
05 Jan 2019
Historique:
received:
20
06
2018
accepted:
24
12
2018
entrez:
7
1
2019
pubmed:
7
1
2019
medline:
7
1
2019
Statut:
epublish
Résumé
Although outcomes of critically ill patients with haematological malignancies (HMs) have been fully investigated in terms of organ failure and mortality, data are scarce on health-related quality of life (HRQOL) in this population. We aim to assess post-intensive care unit (ICU) burden and HRQOL of critically ill patients with HMs and to identify risk factors for quality-of-life (QOL) impairment. In total, 1011 patients with HMs who required ICU admission in 17 ICUs in France and Belgium were included in the study; 278 and 117 patients were evaluated for QOL at 3 months and 1 year, respectively, after ICU discharge. HRQOL was determined by applying the interview form of the Short Form 36 (SF-36) questionnaire. Psychological distress symptoms were evaluated using the Hospital Anxiety Depression Score (HADS) and the Impact of Event Scale (IES). In-hospital mortality rates at 3 months and 1 year were, respectively, 39.1, 50.7 and 57.2%, respectively. At 3 months, median [IQR] physical and mental component summary scores (PCS and MCS) (SF-36) were 37 [28-46] and 51 [45-58], respectively. PCS was lower in ICU patients with HMs when compared to general ICU septic patients (52 [5-13], p = 0.00001). The median combined HAD score was 8 [5-13], and the median IES score was 8 [3-16]. However, recovery during the first year after ICU discharge was not consistent in all dimensions of HRQOL. Three months after ICU discharge, the maximum daily Sequential Organ Failure Assessment score and status of the underlying malignancy at ICU admission were significantly associated with MCS impairment (- 0.54 points [95% CI - 0.99; - 0.1], p = 0.018 and - 4.83 points [95% CI - 8.44; - 1.22], p = 0.009, respectively). HRQOL is strongly impaired in critically ill patients with HMs at 3 months and 1 year after ICU discharge. Organ failure and disease status are strongly associated with QOL. The kinetic evaluation of QOL at 3 months and 1 year offers the opportunity to focus on QOL aspects that may be improved by therapeutic interventions during the first year after ICU discharge.
Sections du résumé
BACKGROUND
BACKGROUND
Although outcomes of critically ill patients with haematological malignancies (HMs) have been fully investigated in terms of organ failure and mortality, data are scarce on health-related quality of life (HRQOL) in this population. We aim to assess post-intensive care unit (ICU) burden and HRQOL of critically ill patients with HMs and to identify risk factors for quality-of-life (QOL) impairment.
RESULTS
RESULTS
In total, 1011 patients with HMs who required ICU admission in 17 ICUs in France and Belgium were included in the study; 278 and 117 patients were evaluated for QOL at 3 months and 1 year, respectively, after ICU discharge. HRQOL was determined by applying the interview form of the Short Form 36 (SF-36) questionnaire. Psychological distress symptoms were evaluated using the Hospital Anxiety Depression Score (HADS) and the Impact of Event Scale (IES). In-hospital mortality rates at 3 months and 1 year were, respectively, 39.1, 50.7 and 57.2%, respectively. At 3 months, median [IQR] physical and mental component summary scores (PCS and MCS) (SF-36) were 37 [28-46] and 51 [45-58], respectively. PCS was lower in ICU patients with HMs when compared to general ICU septic patients (52 [5-13], p = 0.00001). The median combined HAD score was 8 [5-13], and the median IES score was 8 [3-16]. However, recovery during the first year after ICU discharge was not consistent in all dimensions of HRQOL. Three months after ICU discharge, the maximum daily Sequential Organ Failure Assessment score and status of the underlying malignancy at ICU admission were significantly associated with MCS impairment (- 0.54 points [95% CI - 0.99; - 0.1], p = 0.018 and - 4.83 points [95% CI - 8.44; - 1.22], p = 0.009, respectively).
CONCLUSION
CONCLUSIONS
HRQOL is strongly impaired in critically ill patients with HMs at 3 months and 1 year after ICU discharge. Organ failure and disease status are strongly associated with QOL. The kinetic evaluation of QOL at 3 months and 1 year offers the opportunity to focus on QOL aspects that may be improved by therapeutic interventions during the first year after ICU discharge.
Identifiants
pubmed: 30612249
doi: 10.1186/s13613-018-0478-3
pii: 10.1186/s13613-018-0478-3
pmc: PMC6320707
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Subventions
Organisme : French Ministry of Health
ID : PHRC AOM 08235
Références
Intensive Care Med. 1999 Jul;25(7):686-96
pubmed: 10470572
Crit Care Med. 2000 Jul;28(7):2293-9
pubmed: 10921555
Anaesthesia. 2001 Jan;56(1):9-14
pubmed: 11167429
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Intensive Care Med. 2003 Mar;29(3):368-77
pubmed: 12536269
Crit Care Med. 2003 May;31(5):1373-81
pubmed: 12771605
Behav Res Ther. 2003 Dec;41(12):1489-96
pubmed: 14705607
J Natl Med Assoc. 2004 Dec;96(12):1661-7
pubmed: 15622699
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Clin Oncol. 2006 Aug 20;24(24):4003-10
pubmed: 16921054
Crit Care. 2007;11(4):R78
pubmed: 17629906
Chest. 2008 Feb;133(2):377-85
pubmed: 17925419
Crit Care Med. 2008 Oct;36(10):2801-9
pubmed: 18766108
Expert Rev Pharmacoecon Outcomes Res. 2004 Apr;4(2):159-63
pubmed: 19807519
Crit Care Med. 2010 Mar;38(3):855-60
pubmed: 20068465
Crit Care Med. 2010 Jul;38(7):1554-61
pubmed: 20473149
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1038-46
pubmed: 20581167
Qual Life Res. 2011 Mar;20(2):287-300
pubmed: 20882358
Haematologica. 2011 Feb;96(2):231-7
pubmed: 21071501
Psychooncology. 2013 Feb;22(2):241-9
pubmed: 22287503
Intensive Care Med. 2013 May;39(5):889-98
pubmed: 23248039
J Clin Oncol. 2013 Aug 1;31(22):2810-8
pubmed: 23752112
Crit Care Med. 2015 May;43(5):1121-9
pubmed: 25654178
Psychooncology. 2015 Nov;24(11):1569-77
pubmed: 25920906
N Engl J Med. 2015 Jun 4;372(23):2185-96
pubmed: 25981908
Ann Intensive Care. 2015 Dec;5(1):53
pubmed: 26055187
Support Care Cancer. 2015 Dec;23(12):3645-52
pubmed: 26314706
Intensive Care Med. 2016 Oct;42(10):1557-1566
pubmed: 27637716
Crit Care. 2016 Nov 6;20(1):360
pubmed: 27816060
Intensive Care Med. 2017 May;43(5):633-642
pubmed: 28204860
Epidemiol Rev. 2017 Jan 1;39(1):71-92
pubmed: 28453622
J Crit Care. 2018 Feb;43:133-138
pubmed: 28892669
Int J Hematol Oncol Stem Cell Res. 2017 Oct 1;11(4):313-318
pubmed: 29340129
Anaesthesia. 2019 Jan;74(1):100-108
pubmed: 30291744
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Psychosom Med. 1979 May;41(3):209-18
pubmed: 472086
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Med Care. 1995 Apr;33(4 Suppl):AS264-79
pubmed: 7723455
Med Care. 1994 Jan;32(1):40-66
pubmed: 8277801
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
J Clin Epidemiol. 1998 Nov;51(11):1013-23
pubmed: 9817119